RxDoctor Payments Data

Shafiq Khokhar, MD

Geriatric Psychiatry · Ozone Park, NYNPI 1871685495

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 63 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Alkermes, Inc. at 24.6% of the total.

$1,397in general payments, 2019–2025

Across 63 payments — averaging $22.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$344
  • Johnson & Johnson$240
  • Otsuka America Pharmaceutical, Inc.$238
  • Lundbeck LLC$161
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$127
  • Teva Pharmaceuticals USA, Inc.$80
  • plus $208 from 5 others

What the payments were for

  • Food & beverage$1,397100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,397 in reported general payments places this provider in the 70th percentile of 45 geriatric psychiatry providers in New York.

See all geriatric psychiatry providers in New York

Medicare billing

Part B allowed, 2024
$91,406
Medicare patients
176
Services billed
923

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl33$48,696
NamzaricMemantine Hcl/Donepezil Hcl29$23,268
TrintellixVortioxetine Hydrobromide13$7,491
Duloxetine Hcl212$6,491
Divalproex Sodium ErDivalproex Sodium182$6,030
Quetiapine Fumarate279$4,535
Clonazepam454$4,015
VyvanseLisdexamfetamine Dimesylate11$3,897
Aripiprazole102$3,468
Doxepin Hcl34$2,232
Gabapentin230$2,104
Adderall XrDextroamphetamine/Amphetamine11$2,050
Trazodone Hcl217$1,935
Clozapine25$1,859
Carbamazepine ErCarbamazepine43$1,801

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Namzaric$38$71,96462 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 45 geriatric psychiatry providers in New York.

Other geriatric psychiatry in Ozone Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →